Zentalis Pharmaceuticals, Inc.
- Close
- Oct 23, 2026 · -3.70%
- Market cap
- $217.16M
- 98.26M shares
- Filings
- 550
FY 2025−100.0% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026+6.2% FY25 yoy
- $217.16M
- —
- —
- 1.1×
- -57.68%
- —
FY2025 figures · derived
Price
Oct 23, 2026 · Official close
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $0 | reported | |
| FY 2024 | 2024-12-31 | $67,425,000 | reported | |
| FY 2023 | 2023-12-31 | $0 | reported | |
| FY 2022 | 2022-12-31 | $0 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $9.98M | $9.98M | — | 70.93M sh | −1.2% | — |
| FY2024 | — | $0.00 | $0.00 | — | 71.81M sh | +1.2% | — |
| FY2023 | — | $0.00 | $0.00 | — | 70.96M sh | +19.4% | — |
Pharmaceutical preparations
Zentalis Pharmaceuticals, Inc. is the 246th largest of the 552 covered companies the SEC files under this code, by market cap. SIC 2834
CompanyRevenueGrowthNet marginMarket cap
IMRXImmuneering Corp———$237.0MCTNMContineum Therapeutics, Inc.———$226.4MGLSIGreenwich LifeSciences, Inc.———$222.7MINCRIntercure Ltd.———$218.7MACIUAC Immune SA———$217.7M
ZNTLZentalis Pharmaceuticals, Inc. (this company)$0.0100.0%—$217.2M
SIGASiga Technologies Inc$94.6M31.8%24.6%$209.1MTRDAEntrada Therapeutics, Inc.$25.4M87.9%565.5%$203.2MELDNEledon Pharmaceuticals, Inc.———$199.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in market cap first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Zentalis Pharmaceuticals, Inc. · CIK 1725160 · Engraved from SEC EDGAR